Trial · NCT01264939
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| SECONDARY | Change From Baseline to Week 12 in the Weekly Itch Severity Score | Baseline to Week 12 | Modified intent-to-treat population: All randomized patients who received at least 1 dose of study drug. | Units on a scale | MEAN |
| SECONDARY | Change From Baseline to Week 12 in the Urticaria Activity Score Over 7 Days (UAS7) | Baseline to Week 12 | Modified intent-to-treat population: All randomized patients who received at least 1 dose of study drug. | Units on a scale | MEAN |
| SECONDARY | Change From Baseline to Week 12 in the Weekly Number of Hives Score | Baseline to Week 12 | Modified intent-to-treat population: All randomized patients who received at least 1 dose of study drug. | Units on a scale | MEAN |
| SECONDARY | Time to Minimally Important Difference (MID) Response in the Weekly Itch Severity Score by Week 12 | Baseline to Week 12 | Modified intent-to-treat population: All randomized patients who received at least 1 dose of study drug. Only patients with a MID response were included in the analysis. | Weeks | MEDIAN |
| SECONDARY | Percentage of Participants With a UAS7 Score ≤ 6 at Week 12 | Week 12 | Modified intent-to-treat population: All randomized patients who received at least 1 dose of study drug. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Weekly Itch Severity Score MID Responders at Week 12 | Baseline to Week 12 | Modified intent-to-treat population: All randomized patients who received at least 1 dose of study drug. | Percentage of participants | NUMBER |
| SECONDARY | Change From Baseline to Week 12 in the Weekly Size of the Largest Hive Score | Baseline to Week 12 | Modified intent-to-treat population: All randomized patients who received at least 1 dose of study drug. | Units on a scale | MEAN |
| SECONDARY | Change From Baseline in the Overall Dermatology Life Quality Index (DLQI) Score at Week 12 | Baseline to Week 12 | Modified intent-to-treat population: All randomized patients who received at least 1 dose of study drug and who had a DLQI score at Week 12. | Units on a scale | MEAN |
| SECONDARY | Percentage of Angioedema-free Days From Week 4 to Week 12 | Week 4 to Week 12 | Modified intent-to-treat population: All randomized patients who received at least 1 dose of study drug. Patients who withdrew before the Week 4 visit or who had missing responses for more than 40% of the daily diary entries between the Week 4 visit and the Week 12 visit were not included in the analysis. | Percentage of days | MEAN |
| SECONDARY | Percentage of Complete Responders (UAS7 = 0) at Week 12 | Week 12 | Modified intent-to-treat population: All randomized patients who received at least 1 dose of study drug. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With Adverse Events | Baseline to the end of study (up to 40 weeks) | Safety population: All randomized participants who received at least 1 dose of study drug. | Percentage of participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01264939/outcomes